NRF2-associated epigenetic modifications have been shown to act as crucial mechanisms in diabetic cardiomyopathy (DCM), with some literature indicating that epigenetic modifications can promote DCM, while other studies suggest that they inhibit DCM. Here, NFE2L2 is linked to familial dilated cardiomyopathy.